UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2018
Commission File Number001-37965
TiGenix
Romeinse straat 12
3001 Leuven, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101 (b)(1).
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101 (b)(7).
Yes ☐ No ☒
ITEM 1 - INFORMATION CONTAINED IN THIS FORM6-K REPORT
Attached as Exhibit 99.1 is a copy of the Q&A in respect of Takeda Pharmaceutical Company Limited’s intention to acquire TiGenix, dated July 13, 2018.
ITEM 2 - EXHIBITS
The following exhibit is filed as a part of this report:
| | |
Exhibit Number | | Exhibit Description |
| 99.1 | | Q&A in respect of Takeda Pharmaceutical Company Limited’s intention to acquire TiGenix, dated July 13, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | |
| | TIGENIX |
| Date: July 13, 2018 | | | | |
| | By: | | /s/ Claudia D’Augusta |
| | | | Name: Claudia D’Augusta |
| | | | Title: General Manager |
